Bluenote

Market position

Positioned as an enterprise-wide platform for life sciences documentation rather than a single-workflow point solution, targeting large pharma, medical device, diagnostics, CRO and CDMO organizations. A venture directory lists the company at seed stage in the healthcare and digital health sector with a B2B SaaS model and names Carta Healthcare, Notable Health, Bluu Biosciences, Biostate AI and Nuanced Health as similar companies.

Stated differentiators include traceability of every output to source data, fine-tuned domain models reported as 90% preferred over off-the-shelf models, a single secure platform where the same proprietary knowledge base and workflow outputs feed multiple applications, side-by-side accuracy comparisons against manually written documents, and enterprise controls including on-premise hosting and zero data retention.

Technology

Bluenote combines guardrails with custom large language models and domain-optimized Retrieval-Augmented Generation that ingests data from data lakes and third-party applications and indexes it for application-specific requirements. It uses a multi-model approach, mixing models from Anthropic, OpenAI and Google with its own fine-tuned models trained on proprietary datasets, and continuously re-evaluates model configurations. Outputs are engineered to include only factual details from traceable primary sources, with call-to-action placeholders where human reviewers must add context. The platform integrates with ELN, QMS/DMS, data warehouses and data lakes, links every output to source data, and offers SOC 2 Type II and HIPAA alignment, SAML SSO, IP allowlisting, no training on customer data, zero data retention with LLMs, and on-premise deployment.

Go-to-market

Direct enterprise sales via demo requests on its website, supported by named customer references (Guardant Health), industry-leader endorsements, participation in industry events such as an "AI x Bio" panel featuring leaders from Amgen, Guardant Health and Lux Capital, and channel-style partnership with CRO CMIC.

Pharmaceutical and biopharma companies, medical device makers, diagnostics companies, CROs and CDMOs; within those organizations, research, clinical, manufacturing, regulatory and quality functions, including regulatory writers, scientists, engineers and subject-matter experts.

Geography

Headquartered in San Francisco, with a CRO partnership targeting clinical programs in Japan and internationally.

History

Bluenote announced $10M in financing led by Lux Capital in December 2024, stating that proceeds would expand the platform to additional mission-critical, time-intensive workflows. The company subsequently announced a partnership with CMIC Co., Ltd., described as one of Asia-Pacific's largest CROs, to accelerate clinical development, and has been featured in an Anthropic case study on its document-generation agents.